AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q3 2014 Earnings Presentation

27 slides from AMAG Pharmaceuticals's earnings presentation, Oct 30, 2014

  1. Slide 1: AMAG Pharmaceuticals Third Quarter Financial Results

    AMAG Pharmaceuticals Third Quarter Financial Results October 30, 2014

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, stateme

  3. Slide 3: Agenda

    Agenda 2 Topic Speaker Opening Remarks Acquisition of Lumara Health Bill Heiden, CEO Feraheme Update Future Expansion Opportunities Frank Thomas, COO Financial Highlights & Outlook Scott Holmes, SVP of Finance and IR Closing Remarks Bill Heiden, CEO

  4. Slide 4: Building a High-Growth, Multi-Product Specialty Pharmaceutical Company

    EXPERIENCED MANAGEMENT TEAM CORPORATE INFRASTRUCTURE Building a High-Growth, Multi-Product Specialty Pharmaceutical Company HEMATOLOGY/ONCOLOGY, HOSPITAL, NEPHROLOGY FERAHEME® MUGARD® TWO HIGH-PERFORMING SPECIALTY COMMERCIAL TEAMS LUMARA - MATERNAL HEALTH MAKENA®

  5. Slide 5: Third Quarter 2014 Highlights

    Third Quarter 2014 Highlights Entered into definitive agreement to acquire Lumara Health Will add high-growth Makena product Exceptional growth trend continues in 3Q14 Integration planning underway Transaction expected to close 4Q14 Projected pro forma combined 2015 product sales of ~$350 million St

  6. Slide 6: Acquisition of Lumara Health

    ACQUISITION OF LUMARA HEALTH

  7. Slide 7: Acquisition of Lumara Health Transaction Highlights

    Acquisition of Lumara Health Transaction Highlights Upfront consideration of $675MM and up to $350MM of additional consideration based on Makena sales, including milestone payments at $300MM, $400MM and $500MM in annual Makena revenue(1) Makena is the only FDA-approved product to lower the risk of p

  8. Slide 8: Strong Makena Efficacy Data

    Strong Makena Efficacy Data(1)(2) Before 37 weeks Overview 7 Only FDA-approved drug indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have spontaneously delivered one baby preterm in the past Administered intramuscularly (1 mL weekly) between 16-37 weeks o

  9. Slide 9: Transformed Financial Profile of Combined Company

    $ in millions AMAG Lumara Combined Key Product Areas & Number of Marketed Products Hematology / Oncology / Hospital, Supportive Care 2 Maternal Health 1 Maternal Health Hematology / Oncology / Hospital, Supportive Care 3 L3MA(1) 8/31/14 Revenue $100.2 $188.1 $288.3 L3MA(1) (3) 8/31/14 Adjusted EBITD

  10. Slide 10: And Makena Continues to Perform

    And Makena Continues to Perform Strong sequential growth over the last 2+ years ($ in millions) (‘000 vials) Consistent & Strong Growth in Makena’s Prescriptions Makena Historical Sales (FY Ended March 31) Strong quarterly growth through 3Q14 14% increase in vials shipped (3Q14 vs. 2Q14) $46MM-$48MM

  11. Slide 11: Future Expansion Opportunities: Makena Line Extension/Lifecycle Management

    2016 2017 2018 2019 2020 2015 Future Expansion Opportunities Makena Line Extension/Lifecycle Management Routes of Administration Drug Delivery Technologies Reformulation Technologies

  12. Slide 12: Lumara Health Integration Plans

    Integration Support Synergy & Value Capture Organization Management Team AMAG management team and headquarters remain intact Lumara Health will operate as a separate maternal health business unit Synergy targets identified Single sites for each company allow for quick evaluation and implementation o

  13. Slide 13: Feraheme Update

    FERAHEME UPDATE

  14. Slide 14: Feraheme Sales Performance

    Feraheme Sales Performance Ex-factory net sales* ($ in millions) *Excludes the impact of changes in estimates made to product returns and Medicaid reserves in 2012 and 2013 3Q14 vs. 3Q13 20% growth* (+10% volume, +10% price)

  15. Slide 15: Feraheme Demand Growth, Market Share and Evolution Index

    Source: IMS Health Data. *Evolution Index = Product growth divided by market growth Overall Feraheme Demand Growth Market Share & E.I. 3Q14 vs. 3Q13 Hospital segment 11.6% market share; E.I. 117 Hem/Onc segment 25.1% market share; E.I. 85 -7.7% +21.4% 3Q12 3Q14 3Q14 vs. 3Q13 2.5% growth Evolution In

  16. Slide 16: Competitive Landscape: U.S. IV Iron Market

    Competitive Landscape U.S. IV Iron Market ~900,000 Grams Annually *Aggregate of Ferrlecit® Brand + Generic Ferric Gluconate 3Q14 Share of Non-dialysis Market (Grams) Venofer® Iron Dextran / Dexferrum Injectafer® * Ferric Gluconate 16.3% (vs. 16.3% 2Q14) Source: IMS Health Data. 14.0% 42.6% 7.0% 20.1

  17. Slide 17: Feraheme Growth Opportunities: Current CKD Market and Potential IDA Label Expansion

    Feraheme Growth Opportunities: Increase Share of Current CKD Market & Plan for Potential IDA Label Expansion ~$500 million Feraheme potential (900,000 grams**) IDA- CKD IDA Label Expansion Opportunity** Same call audience: Hematology/Oncology Expand use to all IDA patients in current accounts Conver

  18. Slide 18: Opportunity to Grow U.S. IV Iron Market

    Opportunity to Grow U.S. IV Iron Market IV Iron IDA-CKD IV Iron IDA* IV Iron IDA* IV Iron IDA-CKD IDA Expansion Opportunity* IDA-CKD Expansion Opportunity *If regulatory approval is pursued and received.

  19. Slide 19: Regulatory Update: Feraheme & Rienso

    Regulatory Update: Feraheme & Rienso Feraheme - U.S. U.S. broad IDA label 2Q14/3Q14 - Continued interaction with FDA regarding study design 4Q14 - Determination of potential path forward U.S. Feraheme label changes 4Q14 – Expected implementation of proposed changes to strengthen warnings and precaut

  20. Slide 20: Future Expansion Opportunities

    2016 2017 2018 2019 2020 2015 Future Expansion Opportunities Feraheme IDA Approval(1) IV Iron Market Expansion Business Development Oncology/hematology Women’s Health Makena Line Extension/Lifecycle Management(1) Routes of Administration Drug Delivery Technologies Reformulation Technologies MuGard G

  21. Slide 21: Financial Highlights & Outlook

    FINANCIAL HIGHLIGHTS & OUTLOOK

  22. Slide 22: Third Quarter Financial Highlights

    Third Quarter Financial Highlights ($ in millions) 3Q13 3Q14 U.S. Feraheme net sales $19.3 $22.5 Total revenues $21.6 $25.5 Feraheme gross profit $16.8 $19.7 R&D expenses $4.5 $5.4 SG&A expenses $14.9 $12.9(1) Operating income (loss) $(0.4) $4.3 Net income (loss) $(0.1) $1.5 Cash and investments $21

  23. Slide 23: 2014 Financial Outlook

    2014 Financial Outlook ($ in millions) Original 2014 Guidance(1) Updated July 2014 (1) (2) Total revenues $88 - $100 $93 - $102 U.S. Feraheme net sales $75 - $85 $80 - $87 Feraheme COGS (% of Feraheme global net sales) 14% - 16% 13% - 15% Operating expenses $80 - $85 $87 - $92 Net loss ($10 - $12) (

  24. Slide 24: 2014 Goals

    2014 Goals 23 Maximize Feraheme opportunities Drive market share within current U.S. IDA-CKD indication Optimize net revenue per gram Potential label expansion: broad IDA Determine regulatory path forward in U.S. Expected CHMP opinion – 4Q14 Pursue IV iron market expansion initiatives in IDA-CKD Dri

  25. Slide 25: Well positioned for success in 2014... and beyond

    Well positioned for success in 2014. . . and beyond.

  26. Slide 26: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation ($ in millions) Q3 2013 Q3 2014 9 months ended Sept. 2013 9 months ended Sept. 2014 Net income (loss) $(0.1) $1.5 $(5.9) $(7.1) Interest expense and amortization of debt discount and deferred financing costs $ - $3.1 $ - $7.7 Depreciation & amortization $ 1.6 $0.3 $ 2.

  27. Slide 27: Adjusted EBITDA Reconciliation (for L3MA 8/31/14)

    Adjusted EBITDA Reconciliation (for L3MA(1) 8/31/14) ($ in millions) 3 months ended Aug. 2014 (AMAG) 3 months ended Aug. 2014 (Lumara) Net income (loss) $(0.4) $7.7 Interest expense and amortization of debt discount and deferred financing costs $3.1 $0.9 Depreciation & amortization $0.2 $14.9 Intere

Amag Pharmaceuticals — Q3 2014 Earnings Presentation on 6ix